[videopack id=”4889″]https://winip.news/wp-content/uploads/2023/12/stroke-phizer.mp4[/videopack]
December 26, 2022 • by Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt
Review from data in these Pfizer documents… 
5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021 (a.k.a., “5.3.6“).
Social Media has banned this article
Within the stroke data set, there are 275 patients with 300 different events reported; and ….
20% of the stroke events were fatal.
It is important to note that the Adverse Events in the 5.3.6 document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product.
Please read the full report below.
. The stroke category comprises the diagnoses of strokes attributed to either obstruction of blood flow through arteries to areas of the brain or due to bleeding around or into the brain. Within the stroke data set, there are 275 patients with 300 different events reported; and 20% of the stroke events were fatal. It is important to note that the Adverse Events in the 5.3.6 document were reported to Pfizer for only a 90-day period starting on December 1, 2020, the date of the United Kingdom’s public rollout of Pfizer’s COVID-19 experimental mRNA “vaccine” product.){kind=link}